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Summary
Activated articular chondrocytes produce large amounts of nitric oxide (NO), and there is increasing evidence that this is involved in the
etiopathogenesis of osteoarthritis (OA). Because of its short half-life, the biological effects of endogenously produced NO are likely to occur
locally within the cartilage. We have observed that inhibitors of NO synthases relieve the inhibition of matrix synthesis that otherwise occurs
in response to IL-1. To avoid the use of inhibitors, we have recently transduced chondrocytes with the iNOS (NOS-2) gene and confirmed
the ability of the endogenously produced NO to inhibit matrix synthesis. Despite the high levels of NO made by these cells, there was no
evidence of apoptosis or other forms of cell death. NO was also shown to inhibit the production of TGF-â1 by cells treated with IL-1, as well
as to decrease matrix production in response to IGF-1. The hypothesis that NO inhibits matrix production by interfering with important
autocrine and paracrine factors should be entertained.
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Much evidence implicates nitric oxide (NO) in the patho-
physiology of osteoarthritis (OA), including the elevations in
NO−x existing in the serum and synovial fluid of patients
with OA.1,2 Although the origin of the NO is unknown,
articular chondrocytes are likely to be the major intra-
articular source. Activated articular chondrocytes produce
as much, if not more, NO than any other cell in the body.3
Unlike chondrocytes recovered from normal human
articular cartilage, chondrocytes recovered from patients
with OA produce NO spontaneously4 and express NO
synthase (NOS).5 When stimulated in culture, articular
chondrocytes express the inducible isoform of NOS (iNOS
or NOS II).6 However, chondrocytes within human OA
cartilage may express an unusual species of NOS, possibly
a dysregulated neuronal NOS (nNOS or NOS I).5 This
matter awaits clarification.
Endogenously produced NO suppresses the syn-
thesis of the cartilaginous matrix;7 its possible role as a
catabolic mediator remains controversial.8–11 There is
also evidence that NO induces apoptosis in articular
chondrocytes, while protecting them from necrosis in
response to other reactive oxygen species.12 According
to Hashimoto et al.,13 the remnants remaining after
apoptotic death of the chondrocytes become matrix
vesicles and thus participate in the mineralization that
occurs during OA.
Our studies have focused on the mechanisms through
which NO inhibits matrix synthesis by chondrocytes. Here
we review recent progress.377Methods
Primary, monolayer cultures of lapine articular chondro-
cytes were established by standard methods. Certain con-
firmatory experiments were conducted using organ cultures
of cartilage fragments sliced form the femoral condyles of
rabbits’ knees.
High levels of NO synthesis were produced by incu-
bation with 2 ng/ml human, recombinant interleukin-1â
(hrIL-1â) or by infecting cells with an adenovirus carrying
the human NOS-II gene under the control of a cytomega-
lovirus early promoter (ad-iNOS). A similar vector carrying
the lac Z gene (ad-LacZ) was used as a control in certain
experiments; sepiapterin was added as a precursor of
tetrahydrobiopterin. NO production was estimated from the
accumulation of nitrite in conditioned medium. N-methyl-L-
arginine (NMA) was used to inhibit NOS activity.
Synthesis of proteoglycan was measured by the in-
corporation of 35SO42− into macromolecular material. Col-
lagen synthesis was measured by the incorporation of
[3H-proline into collagenase-sensitive proteins. Transform-
ing growth factor-â (TGF-â), insulin-like growth factor-1
(IGF-1) and isoform specific antibodies against TGF-â were
purchased from commercial sources.
Cell death was assessed both visually and by TUNEL
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Cells infected with the ad-iNOS vector, but not the ad-lac
Z vector, produced copious amounts of NO for the entire
10-day culture period (data not shown). Sepiapterin
increased these levels even further. Unlike the case with
untransduced cells stimulated with hrIL-1â,8 NO production
did not decline rapidly after 24–48 h of culture (data not
shown).
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markedly inhibited the synthesis of both proteoglycan and
collagen; NO production was suppressed, and inhibition of
matrix synthesis relieved, by addition of 0.5 mM NMA.
These data confirm that NO is capable of inhibiting
matrix production in the absence of the other metabolic
changes provoked by IL-1.
Even though the ad-iNOS transduced cells were
producing supraphysiological amounts of NO, there was no
evidence of apoptosis or other modes of cell death.NO AND GROWTH FACTORS
NO has been reported to inhibit the production of, and
response to, TGF-â by mesangial cells.14 In chondrocytes,
NO was shown to inhibit the production of TGF-â1, but not
TGF-â2 or â3, by cells treated with hrIL-1â. Moreover, NO
inhibited the autoinduction of TGF-â. There was no effect of
NO on the activation of latent TGF-â1.15
Experiments using neutralizing antibodies to TGF-â1
confirmed the importance of this autocrine factor in main-
taining proteoglycan synthesis in response to IL-1â. In
brief, these antibodies completely blocked the ability of
NMA to antagonize the inhibition of proteoglycan synthesis
by IL-1 (figure). This strongly suggests that NMA’s ability to
reverse this inhibition is mediated via TGF-â1.15
Under the experimental conditions used here, NO
blocked the synthesis of TGF-â1 but not responses to
TGF-â.
In preliminary experiments, we have shown that NO also
antagonizes the ability of IGF-1 to stimulate proteoglycan
synthesis (data not shown). Of interest in the present
context is the observation that matrix synthesis by chondro-
cytes retrieved from osteoarthritic joints is resistant to the
16stimulatory effects of IGF-1.Discussion
These data suggest that the inhibitory effects of NO upon
matrix synthesis reflect its ability to interfere with theproduction of, and responses to, the autocrine factors
TGF-â and IGF-1. They do not, however, shed light on the
mechanisms through which NO interferes with these
autocrine loops.
These findings are of additional interest in light of the
altered responses to TGF-â17 and IGF-116 of chondrocytes
retrieved from osteoarthritic joints. The refractory behavior
of OA chondrocytes to IGF-1 is thought to reflect the high
production of IGF binding proteins by these cells.16 The
latter may reflect alterations in PGE2 production occurring
in response to NO. The involvement of NO in insensitivity to
IGF-1 is strongly suggested from the data obtained recently
using iNOS−/− mice.18
The responses of chondrocytes to TGF-â, in contrast,
are increased in OA.17 Our data suggest that production of
TGF-â by chondrocytes is reduced by NO, but they do not
directly address possible effects on responses to TGF-â.
Collectively, these data strengthen the case for the involve-
ment of NO in OA and other circumstances of altered
cartilage metabolism.200
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Fig. 1. Antibody to TGF-â1 blocks the ability of NMA to restore
proteoglycan synthesis by chondrocytes treated with IL-1â. Values
are means±SE (N=6). *=P<0.05 vs vehicle control. #=P<0.05 vs
cells treated with IL-1â and NMA. , Control; , IL-1; ,
IL-1+NMA; , TGF-beta. References
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